Company Overview
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.07.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +12.21% |
| 6 Months: | +35.92% |
| 3 Months: | +67.83% |
| 1 Month: | +53.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross4d ago
- RSI (14)71.53 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 27.7% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BMEA Biomea Fusion, Inc. PHARMA | 1.93 | -10.72 | $139.89M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 1.07B | - | - | - | 1.07B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -398.00K | -295.00K | -1.14M | -3.50M | -5.86M | -8.44M | -12.64M | -14.74M | -16.40M | -17.47M | -23.48M | -26.28M | -30.03M | -27.66M | -31.12M | -37.33M | -41.06M | -38.90M | -34.04M | -30.07M | -29.71M | -21.28M | -20.80M | -12.77M | -12.77M |
| Net Income | -398.00K | -293.00K | -1.14M | -3.50M | -5.85M | -8.40M | -12.61M | -14.71M | -16.37M | -17.26M | -22.89M | -25.31M | -29.05M | -24.89M | -28.43M | -34.88M | -39.06M | -37.28M | -32.79M | -29.30M | -29.26M | -20.74M | -16.41M | -12.41M | -8.33M |
| Diluted EPS | - | - | - | - | -0.49 | -0.33 | -0.43 | -0.51 | -0.56 | -0.59 | -0.78 | -0.86 | -0.98 | -0.70 | -0.80 | -0.98 | -1.09 | -1.03 | -0.91 | -0.81 | -0.80 | -0.51 | -0.27 | -0.17 | -0.12 |
| R&D Expense | 334.00K | 216.00K | 789.00K | 2.33M | 3.80M | 5.22M | 7.89M | 11.09M | 11.35M | 12.58M | 18.24M | 20.54M | 24.39M | 21.94M | 25.35M | 30.87M | 33.78M | 31.82M | 27.24M | 25.24M | 22.90M | 16.57M | 14.40M | 9.12M | 9.14M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 83.63M | 126.14M | 144.07M | 81.31M |
| Operating Income | -1.20M | -5.33M | - | -83.63M | -126.14M | -144.07M | -81.31M |
| EBITDA | - | - | - | -82.94M | -124.62M | -142.32M | -79.90M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -81.83M | -117.25M | -138.43M | -61.80M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -1.20M | -5.32M | - | -81.83M | -117.25M | -138.43M | -61.80M |
| Diluted EPS | - | -0.51 | - | -2.80 | -3.44 | -3.83 | -1.18 |
| R&D Expense | 1.09M | 3.67M | 28.00M | 62.71M | 102.55M | 118.08M | 61.98M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 62.53M | 185.71M | 129.31M | 199.93M | 79.94M | 58.57M |
| Total Equity | -263.00K | -21.00K | 5.17M | 178.78M | 108.54M | 169.24M | 51.57M | 29.55M |
| Cash & Equivalents | - | 239.00K | 61.70M | 145.74M | 111.90M | 176.87M | 58.28M | 55.81M |
| Total Liabilities | - | - | 1.62M | 6.92M | 20.77M | 30.69M | 28.36M | 29.02M |
| Current Liabilities | - | - | 1.62M | 4.64M | 19.10M | 22.86M | 21.67M | 11.10M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.28M | -4.46M | -35.44M | -62.42M | -96.59M | -119.89M | -70.37M |
| Investing Cash Flow | - | -51.00K | -33.35M | 27.34M | -2.22M | -362.00K | - |
| Financing Cash Flow | 1.44M | 65.97M | 153.19M | 1.24M | 163.80M | 1.67M | 67.90M |
| Capital Expenditure | - | -51.00K | -3.17M | -1.03M | -3.37M | -362.00K | - |
| Free Cash Flow | - | -4.51M | -38.61M | -63.45M | -99.96M | -120.26M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 5,704.8% | -103.0% | - | -75.4% | -69.3% | -268.4% | -209.1% |
| ROCE % | - | -8.7% | - | -75.9% | -71.2% | -247.3% | -171.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 12.16% | 8.81M | $16.13M |
| 2 | Vanguard Capital Management LLC | 3.90% | 2.83M | $5.18M |
| 3 | Marshall Wace LLP | 2.83% | 2.05M | $3.75M |
| 4 | Aisling Capital Management LP | 2.83% | 2.05M | $3.75M |
| 5 | Renaissance Technologies, LLC | 2.01% | 1.46M | $2.66M |
| 6 | Fideuram - Intesa Sanpaolo Private Banking S.p.a. | 1.00% | 723.18K | $1.32M |
| 7 | Blackrock Inc. | 0.99% | 715.45K | $1.31M |
| 8 | Geode Capital Management, LLC | 0.98% | 708.85K | $1.30M |
| 9 | Susquehanna International Group, LLP | 0.85% | 612.74K | $1.12M |
| 10 | Mariner, LLC | 0.82% | 594.73K | $1.09M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BMEA
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOX1NwZFRReHZYUDFYeTExaXoxRWt2MENCQWNxZkJzTEJTVnprQzE1cklQVldvQUUtM2FXTkp2OXprXzJZZGxfa1l5Yy0yNlhGMzBmNzJySVlaeGlMWVBHeWRXLTY0eWFydXh5UnlJVFFmV0Q1UjI1Y3Jjby1Rb0tFYWVmajNZek5hcTdDSW…
What date does BIOMEA FUSION's (BMEA) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTE9DVld4b3hmZVRqN3pHa21lVlgwZ2ZVWG02c3FtMi1QVUE2cm9IVFdYbjRlNFh1cmpRX2RsRko3NGs3Qm5FX1AtYWVjNXRVUEk1UHIzRkQ0ZTRONS1PSjVyZUZhZzVsNlB6TWhz?oc=5" target="_blank">What date does BIOMEA F…
BMEA Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5tR1NYMkhQbGZVSzdJOVFJY2RUWm1nSjI5QWJFODlVYjFUM3FWSnNqZGlJaTl5MlhRdy0yMkJZejYtcDRmd2xpVUxieVNJTnlDNHdYaGpFQ0xCTlBMZlZhVE9vVWlCSkVRMkoyNGNMSXFkMFVQWkxqVy1R?oc=5" target="_blank">BME…
Biomea Fusion Stock (BMEA) Opinions on Clinical Milestones and Liquidity Concerns - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQRG1GMkR1YVFhdUtoQ3I3d1d1VkNmbm5lTndGUW1DN0oyS1QxQ2VmYTdPYXR6X3RNd1FhVTczWmZ6ZDNLSmQxQTQ4M2o4QUJrUUNvNHZnU0VHZVBIazFTSllmQUVtMHEtaHVqb0FFN0UxRTFXLXkyU2ZHVFppcVNGb2RicnYtY3RzbFZOdW…
Insiders Buying Biomea Fusion Might Wish They Invested More, Stock Gains 12% - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQS2NfWVp2aDBMaHpsdHlSQ0xiMG5kcnBxeXRxYjRSM2FxRHNObENicGt4dVNhdGFObHBDOVhKOHlUc3VWeE54Z1p2aWRsUDBEV0lHTDRLZmxXV0MzZW9PdGVKYmhBZ3dZTWIzMmZwdVZ1NVZ3VTRocXVFWlZDanljbENTbVh1YmgxZlNNNG…
Biomea Fusion (BMEA) director granted 196,299 stock options at $1.15 exercise price - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNZ1lDV0tPY0RGRUJjeE5LWVF1NVlsUjBoeTRNM2xOM3BVdHNBdjVPOTZJMEM1eGY1ZHhqdUN6NkdNQUVZNWk2cnAwcEhRSjEzNUFudG02bVJ3dG03Y01YTEwySUxIRVFrMTB5UU1Oa1ltbXNZVkExLUxCU1JmR3lfY1MzU2ZTMEtNMl96Zj…
BMEA — Frequently Asked Questions
What is the current share price of Biomea Fusion, Inc. (BMEA)?
As of 2026-09-19 21:16 PDT, Biomea Fusion, Inc. (BMEA) trades at $1.93 on NasdaqGS. Its 52-week range is $0.96 to $2.67.
What is the market capitalisation of BMEA?
Biomea Fusion, Inc. (BMEA) has a market capitalisation of $139.89M on NasdaqGS.
What is the P/E ratio of BMEA?
BMEA trades at a trailing price-to-earnings (P/E) ratio of -10.72. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 11.05.
Is BMEA a good stock to buy?
This page provides a data-driven analysis of Biomea Fusion, Inc. (BMEA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.